Abstract:Background: Neurofilament light chain protein (NfL) in cerebrospinal fluid (CSF) reflects the severity of neurodegeneration, with its altered concentrations discovered in Parkinson's disease (PD) and Parkinson's disease dementia (PD-D). Objective: To determine whether CSF NfL, a promising biomarker of neuronal/axonal damage, can be used to monitor cognitive progression in de novo Parkinson's disease and predict future cognitive decline. Methods: A total of 259 people were recruited in this study, including 85 healthy controls (HC) and 174 neonatal PD patients from the Parkinson's Progression Markers Initiative (PPMI). Multiple linear regression and linear mixed effects models were used to examine the associations of baseline/longitudinal CSF NfL with cognitive decline and other CSF biomarkers. Kaplan–Meier analysis and log-rank test were used to compare the cumulative probability risk of cognition progression during the follow-up. Multivariate cox regression was used to detect cognitive progression in de novo PD. Results: We found PD patients with mild cognitive impairment (PD-MCI) was higher than with normal cognition (PD-NC) in terms of CSF NfL baseline levels ( p = 0.003) and longitudinal increase rate ( p = 0.034). Both baseline CSF NfL and its rate of change predicted measurable cognitive decline in de novo PD (MoCA, β = −0.010, p = 0.011; β = −0.0002, p < 0.001, respectively). The predictive effects in de novo PD patients aged >65, male, ill-educated (<13 years) and without carrying Apolipoprotein E ε4 ( APOE ε4 ) seemed to be more obvious and reflected in more domains investigated. We also observed that CSF NfL levels predicted progression in de novo PD patients with different cognitive diagnosis and amyloid status. After an average follow-up of 6.66 ± 2.54 years, higher concentration above the median of baseline CSF NfL was associated with a future high risk of PD with dementia (adjusted HR 2.82, 95% CI: 1.11–7.20, p = 0.030). Conclusion: Our results indicated that CSF NfL is a promising prognostic predictor of PD, and its concentration and dynamics can monitor the severity and progression of cognitive decline in de novo PD patients.

Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease

Predictive value of serum neurofilament light chain for cognitive impairment in Parkinson's disease

Plasma neurofilament light chain levels are associated with depressive and anxiety symptoms in Parkinson’s disease

Serum Neurofilament Dynamics Predicts Cognitive Progression in De Novo Parkinson's Disease.

Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson's disease

Clinical significance of serum glial fibrillary acidic protein level in middle-aged and elderly patients with Parkinson's disease

Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease

The association of serum neurofilament light chains with early symptoms related to Parkinson's disease: A cross-sectional study

Serum neurofilament light chain and cognition decline in US elderly: A cross-sectional study

Association of plasma neurofilament light chain and Lipoprotein-related phospholipase A2 with motor subtypes of Parkinson's disease

Plasma Insulin-Like Growth Factor 1 is Associated with Cognitive Impairment in Parkinson's Disease

Plasma neurofilament light chain in relation to 10-year change in cognition and neuroimaging markers: a population-based study

Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men

Neurofilament Light Chain as a Biomarker of Global Cognition in Individuals With Possible Vascular Mild Cognitive Impairment

Association of Cerebrospinal Fluid Neurofilament Heavy Protein Levels with Clinical Progression in Patients with Parkinson Disease

Relationship between plasma NFL and disease progression in Parkinson's disease: a prospective cohort study

Association between serum neurofilament light chains (sNfL) and neurologic disorders in a representative sample of US adults: a cross-sectional study

Circulating Neurofilament Light Predicts Cognitive Decline in Patients With Post-stroke Subjective Cognitive Impairment

Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum

A multicentre validation study of the diagnostic value of plasma neurofilament light

Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment